Opinion statement
Malignant Pleural Mesothelioma (MPM) remains a rare and lethal disease that is directly related to asbestos exposure in the vast majority of cases. While the total number of cases remains low compared to other malignancies, the worldwide incidence is expected to increase over the next twenty years. Currently, survival rates remain dismal and there is no standard therapy or consensus regarding treatment. However, over the last fifteen years there have been substantial improvements in the diagnosis and treatment of MPM, including easier and more accurate diagnostic techniques, improved methods of staging, more effective systemic therapy, a remarkable decrease in operative mortality, marked improvements in local control with adjuvant therapy, and perhaps most important, an emphasis on multidisciplinary care and multimodality clinical trials. Despite these advances, optimal therapy for these patients remains highly controversial and the role of surgery is actively debated. Most controversy centers on whether surgery increases survival and whether a survival benefit is best achieved with extrapleural pneumonectomy or pleurectomy/decortication within a multimodal regimen. To date, trimodality therapy that includes surgery, chemotherapy, and radiation offers the best survival advantage. It is generally accepted that the main goals of surgery, within the framework of a multimodality approach, is not only complete resection if possible, but more realistically, the resection of all macroscopic disease as an adjunct to the delivery of chemotherapy and radiation. The surgical options available to obtain this goal include extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). There are no randomized trials directly comparing EPP and P/D and the level of evidence supporting either technique remains low. Ultimately, the choice of operation depends on multiple factors including: disease stage, the patient’s cardiopulmonary reserve, surgeon experience and philosophy, and the extent of planned adjuvant therapy. Yet, despite the inherent biases in most studies, the data thus far illustrates significant survival advantages with both P/D and EPP and surgeons should consider these approaches in select patients.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
National Cancer Institute: Surveillance Epidemiology and End Results: Cancer Statistics. Available at http://seer.cancer.gov/statistics.
Ismail-Khan R, Robinson LA, Williams Jr CC, et al. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006;13(4):255–63.
Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260–71.
Merritt N, Blewett CJ, Miller JD, et al. Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol. 2001;78:171–4.
Hulks G, Thomas JS, Waclawski E. Malignant pleural mesothelioma in western Glasgow 1980–6. Thorax. 1989;44:496–500.
Flores RM, Riedel E, Donington JS, et al. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (surveillance. Epidemiology, and end results [SEER]) population. J Thorac Oncol. 2010;5:1649–54.
Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 322 patients. J Clin Oncol. 1989;7:1157–68.
Treasure T, Waller D, Tan C, et al. The mesothelioma and radical surgery randomized controlled trial, the MARS feasibility Study. J Thor Oncol. 2009;4:1254–8.
Law MR, Gregor A, Hodson M, Bloom HJG, Turner-Warwick M. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax. 1984;39:255–9.
Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura, experience with 29 patients. Thorax. 1976;31:15–24.
Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma A Lung Cancer Study Group trial. J Thorac Cardiovac Surg. 1991;102:1–9.
Rusch VW, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol. 1994;12:1156–63.
Hilaris BS, Dattatreyudu N, Kwong E, et al. Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 1984;10:325–31.
Sugarbaker DJ, Mentzer SJ, Decamp M, Lynch TJ, Strauss GM. Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma. Chest. 1993;103(suppl):377S–81S.
Sugarbaker DJ, Garcia JP, Richards WG, Harpole DH, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma: results in 120 consecutive patients. Ann Surg. 1996;224:288–94.
Sugarbaker DJ, Flores RM, Jaklitsh MT, et al. Resction margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–65.
Rusch VW, Venkatraman E. Important factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg. 1999;68:1799–804.
Schipper PH, Nichols FC, Thomse KM, et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg. 2008;85:257–64.
Flores RM, Pass HI, Venkatraman E, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620–6.
Aziz T, Jilahawi A, Prakash D. The management of malignant pleural mesothelioma: a single center experience in 10 years. Eur J Cardiothorac Surg. 2007;22:298–305.
Zellos L, Richards W, Capalbo L, et al. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2009;137:453–8.
Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009;138:405–11.
Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with malignant pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995;108:754–8.
Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788–95.
Yajnik S, Rosenzweig K, Mychalczak B, et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;56:1319–26.
Rice DC, Stevens CW, Correa A, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007;84:1685–93.
Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.
Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant mesothelioma. J Clin Oncol. 2004;22:3451–7.
Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007;18:1196–202.
Rea F, Marulli G, Bortolotti L, et al. Induction chemotherapy, extrapleural pneumonectomy in malignant pleural mesothelioma: feasibility and results. Lung Cancer. 2007;57:89–95.
Krug LM, Pass HI, Rusch VW, et al.: Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignat pleural mesothelioma. J Clin Oncol 2009, 27:3007–13.
de Perrot M, Feld R, Cho BC, et al.: Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant hemi-thoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27:1413–8.
Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol. 1994;12:1156–63.
Pass HI, Kranda K, Temeck B, Feuerstein I, Steinberg S. Surgically debulked malignant pleural mesothelioma” results and prognostic factors. Ann Surg Oncol. 1997;4(3):215–22.
Pass HI, Temeck BK, Kranda K, et al. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1998;115:310–7.
Lee TT, Everett DL, Shu HK, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2002;124:1183–9.
Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63:1045–52.
Richards W, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24:1561–7.
Halstead JC, Lim E, Venkateswaran RM, et al. Improved survival with VATS pleurectomy/decortication in advanced malignant mesothelioma. ESJO. 2005;31:314–20.
Bolukbas S, Manegold C, Eberlein M, et al.: Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer 2009, 71:75–81.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kaufman, A.J., Flores, R.M. Surgical Treatment of Malignant Pleural Mesothelioma. Curr. Treat. Options in Oncol. 12, 201–216 (2011). https://doi.org/10.1007/s11864-011-0154-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11864-011-0154-4